his.sePublications
Change search
Refine search result
1 - 1 of 1
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Svensson, Andreas
    University of Skövde, Health and Education.
    In vitro study of the antiproliferative properties of Digitoxin glycosides and Keytruda on BxPC-3 pancreatic cancer2019Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
    Abstract [en]

    In the early 1900s, cancer patients were often treated by inducing a bacterial infection that stimulated an immune response which lead to a spontaneous passive cancer regression. This discovery lead to today’s modern cancer immunotherapy – an approach in which medical interventions stimulate the body’s own immune system to fight cancer cells. Digitoxin glycosides, a sodium pump inhibitor used mainly to treat heart-related diseases has been reviewed in clinical trials for its anti-tumor like properties. Moreover, A new drug to aid in the war against progressive inoperable metastatic cancers was approved 2014 by FDA. Keytruda was the first monoclonal non-chimeric human IgG4 antibody drug to restore the immune response to activated T-cells by interfering with the tumours’ programmed death ligands (PD-L1) and (PD-L2). Cancer cells express an increased level of reactive oxygen species (ROS) that promote cancer cell proliferation and development. However, in too low or high levels, ROS promote oxidative damage in favour of anti-tumor properties. This study evaluated Digitoxin glycosides and Keytruda as potential anti-tumor therapies and any eventual synergic effects. Digitoxin, as mono-therapy, promoted apoptotic behaviour in pancreatic cancer cells when administrated in the mid- to high-end dosage range. Respectively, this study suggests a combination-therapy using a sub-physiological Keytruda-concentration together with a relatively high Digitoxin concentration produce a significant antiproliferative effect.

1 - 1 of 1
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf